BRPI0606647A2 - antagonistas do receptor de c5a - Google Patents
antagonistas do receptor de c5aInfo
- Publication number
- BRPI0606647A2 BRPI0606647A2 BRPI0606647-0A BRPI0606647A BRPI0606647A2 BR PI0606647 A2 BRPI0606647 A2 BR PI0606647A2 BR PI0606647 A BRPI0606647 A BR PI0606647A BR PI0606647 A2 BRPI0606647 A2 BR PI0606647A2
- Authority
- BR
- Brazil
- Prior art keywords
- bonds
- substituted
- radical
- group
- mimics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Abstract
ANTAGONISTAS DO RECEPTOR DE C5a. A presente invenção refere-se a um composto, de preferência um antagonista de receptor de C5a, tendo a seguinte estrutura: segundo a qual X1 é um radical tendo uma massa de cerca de 1 a 300, segundo a qual X1 é de preferência selecionado do grupo que compreende R5-, R5-CO-, R5-N(R6)-CO-, R5-O-CO-, R5-SO2 22-, R5-N(R6)-SO2 22-, R5-N(R6)-, R5-N(R6)-CS-, R5-N(R6)-C(NH)-, R5-CS-, R5-P(O)OH-5, R5-B(OH)-, e R5-CH=N-O-CH2 22-CO-, segundo o que R5 e R6 são individualmente e independentemente selecionados do grupo que compreende H, F, hidróxi, alquila, alquila substituida, cicloalquila, cicloalquila substituida, heterociclila, heterociclila substituida, arilalquila, arilalquila substituida, arila, arila substituida, heteroarila, heteroarila substituida, acila, acila substituida, alcóxi, alcoxialquila, alcoxialquila substituida, ariloxialquila e ariloxialquila substituida, X2 é um radical que imita as características de ligação biológica de uma unidade de fenilalanina, X3 e X4 são individualmente e independentemente um espaçador, segundo o que o espaçador é de preferência selecionado do grupo que compreende aminoácidos, análogos de aminoácidos e derivados de aminoácidos, X5 é um radical que imita as características de ligação biológica de uma unidade de cicloexilalanina ou homoleucina, X6 é um radical que imita as características de ligação biológica de uma unidade de triptofano, X7 é um radical que imita as características de ligação biológica de uma unidade de norleucina ou fenilalanina, uma ligação química entre X3 e X7 é formada, e as linhas de conexão - na fórmula (1) indicam ligações químicas, segundo o que a ligação química é individualmente e independentemente selecionada do grupo que compreende ligações covalentes, ligações iónicas e ligações coordenativas, segundo o que de preferência a ligação é uma ligação química e mais preferivelmente a ligação química é uma ligação selecionada do grupo que compreende ligações de amida, ligações de dissulfeto, ligações de éter, ligações de tioéter, ligações de oxima e ligações de aminotriazina, segundo o que o composto é em particular útil para a fabricação de um medicamento para o tratamento de doenças auto-imunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05000857 | 2005-01-17 | ||
PCT/EP2006/000365 WO2006074964A1 (en) | 2005-01-17 | 2006-01-17 | C5a receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0606647A2 true BRPI0606647A2 (pt) | 2009-07-14 |
Family
ID=36013361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0606647-0A BRPI0606647A2 (pt) | 2005-01-17 | 2006-01-17 | antagonistas do receptor de c5a |
Country Status (14)
Country | Link |
---|---|
US (1) | US20080161232A1 (pt) |
EP (1) | EP1838725A1 (pt) |
JP (1) | JP2008526915A (pt) |
KR (1) | KR20070104355A (pt) |
CN (1) | CN101107264A (pt) |
AU (1) | AU2006205830A1 (pt) |
BR (1) | BRPI0606647A2 (pt) |
CA (1) | CA2594934A1 (pt) |
IL (1) | IL184278A0 (pt) |
MX (1) | MX2007008640A (pt) |
RU (1) | RU2007131267A (pt) |
SG (1) | SG158191A1 (pt) |
WO (1) | WO2006074964A1 (pt) |
ZA (1) | ZA200705237B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011195451A (ja) * | 2008-06-20 | 2011-10-06 | Fukuoka Univ | ペプチド |
US8425662B2 (en) | 2010-04-02 | 2013-04-23 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US9518265B2 (en) * | 2012-01-10 | 2016-12-13 | Noxxon Pharma Ag | C5a binding nucleic acids |
JP6754997B2 (ja) * | 2013-08-26 | 2020-09-16 | 国立大学法人 東京大学 | 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法 |
JO3669B1 (ar) * | 2015-01-06 | 2020-08-27 | Ferring Bv | بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين |
DK3368544T3 (da) | 2015-10-27 | 2020-08-24 | Hoffmann La Roche | Peptidmakrocykler mod Acinetobacter baumannii |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
AU2017304103A1 (en) * | 2016-07-29 | 2019-01-17 | Pfizer Inc. | Cyclic peptides as C5 a receptor antagonists |
EP3388444A1 (en) | 2017-04-10 | 2018-10-17 | F. Hoffmann-La Roche AG | Anti-bacterial peptide macrocycles and use thereof |
US11505573B2 (en) | 2018-03-28 | 2022-11-22 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
US11819532B2 (en) | 2018-04-23 | 2023-11-21 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
US11918624B2 (en) | 2020-06-10 | 2024-03-05 | Kelsius Laboratories LLC | Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2045578A1 (en) * | 1989-01-31 | 1990-08-01 | Megumi Kawai | Anaphylatoxin-receptor ligands |
US5190922A (en) * | 1991-06-04 | 1993-03-02 | Abbott Laboratories | Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands |
AUPO755097A0 (en) * | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
AUPR833401A0 (en) * | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
EP1498422A1 (de) * | 2003-07-17 | 2005-01-19 | Jerini AG | C5a-Rezeptor-Antagonisten |
-
2006
- 2006-01-17 CN CNA2006800025125A patent/CN101107264A/zh active Pending
- 2006-01-17 MX MX2007008640A patent/MX2007008640A/es unknown
- 2006-01-17 JP JP2007550769A patent/JP2008526915A/ja active Pending
- 2006-01-17 RU RU2007131267/04A patent/RU2007131267A/ru not_active Application Discontinuation
- 2006-01-17 US US11/814,050 patent/US20080161232A1/en not_active Abandoned
- 2006-01-17 KR KR1020077016266A patent/KR20070104355A/ko not_active Application Discontinuation
- 2006-01-17 SG SG200908737-0A patent/SG158191A1/en unknown
- 2006-01-17 CA CA002594934A patent/CA2594934A1/en not_active Abandoned
- 2006-01-17 BR BRPI0606647-0A patent/BRPI0606647A2/pt not_active IP Right Cessation
- 2006-01-17 WO PCT/EP2006/000365 patent/WO2006074964A1/en active Application Filing
- 2006-01-17 AU AU2006205830A patent/AU2006205830A1/en not_active Abandoned
- 2006-01-17 EP EP06706265A patent/EP1838725A1/en not_active Ceased
-
2007
- 2007-06-28 IL IL184278A patent/IL184278A0/en unknown
- 2007-07-02 ZA ZA200705234A patent/ZA200705237B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006074964A1 (en) | 2006-07-20 |
CA2594934A1 (en) | 2006-07-20 |
AU2006205830A1 (en) | 2006-07-20 |
RU2007131267A (ru) | 2009-02-27 |
KR20070104355A (ko) | 2007-10-25 |
JP2008526915A (ja) | 2008-07-24 |
CN101107264A (zh) | 2008-01-16 |
ZA200705237B (en) | 2009-06-24 |
EP1838725A1 (en) | 2007-10-03 |
SG158191A1 (en) | 2010-01-29 |
US20080161232A1 (en) | 2008-07-03 |
MX2007008640A (es) | 2007-09-12 |
IL184278A0 (en) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606647A2 (pt) | antagonistas do receptor de c5a | |
JP7325483B6 (ja) | 免疫調節剤としての1,2,4-オキサジアゾールおよびチアジアゾール化合物 | |
ATE423769T1 (de) | Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten | |
EP2116544A3 (de) | Spirocyclische Cyclohexan-Derivate | |
EP2423207A3 (en) | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | |
RU2018106483A (ru) | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr | |
WO2005089118A3 (en) | Novel bicyclic compounds as modulators of androgen receptor function and method | |
EA200301306A1 (ru) | Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение | |
NO20064151L (no) | Nye forbindelser | |
BR9908351A (pt) | Compostos, processo para a preparação dosmesmos, e, composição farmacêutica | |
TW200833326A (en) | Chemical compounds 572 | |
EA200501595A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
TW200510429A (en) | Heterocyclic MCHR1 antagonists | |
FR2894475B1 (fr) | Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine | |
PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
EP2042490A3 (en) | Benzimidazole derivatives as vanilloid receptor antagonists | |
EP1666459A3 (en) | Aminocyclohexyl ether compounds and uses thereof | |
BR0309933A (pt) | (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetraidrofurilc arbonil)-4-piperidinil-metil]-4-piperidinil] benzamida, processo para sua preparação, composição farmacêutica contendo o mesmo e intermediários obtidos desta forma | |
NZ610732A (en) | Novel angiotensin type 2 (at2) receptor agonists and uses thereof | |
EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives | |
DE60226906D1 (de) | 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen | |
EP2518082A3 (en) | Means for the inhibition of anti-beta1-adrenergic receptor antibodies | |
WO2005010030A3 (de) | C5a-REZEPTOR-ANTAGONISTEN | |
WO2006018708A3 (en) | Pyrrolidine derivatives as muscarinic receptor antagonists | |
BR0318242A (pt) | derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2210 DE 14/05/2013. |